Synthon B.v.

Synthon IP Inc.

Rolf Keltjens

Theodorus H A Peters

Lambertus Thijs

Jacobus Maria Lemmens

Johannes Jan Platteeuw

Frantisek Picha

Lisardo Alvarez Fernandez

Jie Zhu

Franciscus B G Benneker

Luis Nogueiras Nieto

Marta Vivancos Martinez

Gerrit J B Ettema

Deepak Murpani

Jacobus Theodorus Henricus Van Eupen

Montserrat Gallego Luengo

Gerrit Jan Bouke Ettema

Inocencia Margallo Lana

Judith Firet

Juan Cucala Escoi

Marinus J M Oosterbaan

Jiri Partl

Ondrej Hylse

The presented invention relates to a process for preparation of compound of formula (I) or a salt or a solvate thereof (i.e.) siponimod. The invention also relates to intermediates used in the process and solid forms of these intermediates.

Process for making Siponimod and intermediate thereof

The present invention relates to a pharmaceutical composition comprising an inclusion complex of amorphous lenalidomide, or a pharmaceutically acceptable salt thereof, in non-substituted &#x3b2;-cyclodextrin and one or more pharmaceutically acceptable excipients. The invention further relates to the use of said composition as a medicament, particularly in the treatment of in the treatment of multiple myeloma and myelodysplastic syndromes.

Pharmaceutical composition comprising amorphous lenalidomide

Asenapine and related trans-isomer bicyclic compounds can be obtained by reducing a compound of formula (C) to preferentially form a trans-isomer compound of formula (D), followed by subsequent ring closure to form a compound of formula (B) such as asenapine. 

Process for making asenapine

Amlodipine free base can be formulated into a convenient oral dosage form, especially a tablet, without excessive stickiness or tablet punch residue. The amlodipine free base can be crystalline Form I or a novel Form II. Methods of making and using the amlodipine free base are set forth.

Amlodipine free base

Olanzapine and salts thereof are made by a process that utilizes an N-formyl olanzapine intermediate of formula (4) or a salt thereof 

Synthesis of olanzapine and intermediates thereof

Bicalutamide and/or its intermediates are made by the use of p-fluorobenzenesulfinic acid salt as a reagent.

Process for making bicalutamide and intermediates thereof

Venlafaxine besylate compounds provide certain advantages over venlafaxine hydrochloride and are useful in forming pharmaceutical compositions and n treating venlafaxine-treatable diseases and conditions. Venlafaxine besylate can be easily formulated into an extended release dosage form including a hydrogel tablet as well as other matrix-based tablet compositions. A preferred tablet making process involves hot melt granulation.

Venlafaxine besylate

Low water soluble salts of venlafaxine, especially venlafaxine maleate, are provided. Such salts can provide a variety of dosage forms including hydrogel-based extended release dosage forms.

Low water-soluble venlafaxine salts

Growing community of inventors

Nijmegen, Netherlands

Rolf Keltjens